Philip Lowry, MD

Guthrie Provider
Care Provider Overall: 
5
Provider Reviews: 
106

Schedule a visit with this provider

Call 866-GUTHRIE (866-488-4743) to make an appointment.

Ask us if a telemedicine appointment is right for you.

Click here for more information.

  • Clinical Details
  • Education
  • Clinical Trials
Hospital Privileges: 
  • Guthrie Robert Packer Hospital
Clinical Interests: 
  • Colorectal Cancer
  • Lung Cancer
  • Telemedicine

Patient Ratings

The Patient Rating score is an average of all responses to care provider related questions on our nationally-recognized Press Ganey Patient Satisfaction Survey. Responses are measured on a scale of 1 to 5 with 5 being the best score.
Likelihood of Recommending Care Provider: 
5
Patients' Confidence in Care Provider: 
5
Time Care Provider Spent with Patient: 
5
Care Provider Spoke Using Clear Language: 
5
Care Provider Efforts to Include in Decisions: 
5
Care Provider's Concern for Questions and Worries: 
5
Care Provider's Explanations of Condition/Problem: 
5
Care Provider Information About Medications: 
5
Care Provider Instructions for Follow-Up Care: 
5
Care Provider's Friendliness and Courtesy: 
5
Residency: 
  • University of Virginia, Charlottesville, Va.
Certification: 
  • American Board of Internal Medicine/Hematology
  • American Board of Internal Medicine/Oncology
Education: 
  • Yale University School of Medicine, New Haven, Conn.
Fellowship: 
  • University of Virginia, Charlottesville, Va.
Department: Oncology
Diagnosis: Lung- Non-Small Cell
Principal Investigator: Lowry MD, Philip
Sub-Investigator(s):
Sponsor: SWOG
Details (Identifier #): NCT03851445
Title: LungMap (Screening Protocol for Lung-Map):
Department: Oncology
Diagnosis: Oncology - General
Principal Investigator: Lowry MD, Philip
Sub-Investigator(s):
Sponsor: ECOG-ACRIN
Details (Identifier #): NCT02465060
Title: MATCH EAY131, Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Department: Oncology
Diagnosis: Breast- Adjuvant
Principal Investigator: Lowry MD, Philip
Sub-Investigator(s):
Sponsor: NRG
Details (Identifier #): NCT02488967
Title: NRG-BR003: Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer
Department: Oncology
Diagnosis: Breast- Metastatic
Principal Investigator: Lowry MD, Philip
Sub-Investigator(s):
Sponsor: NRG
Details (Identifier #): NCT03199885
Title: NRG-BR004: A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab With Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
Department: Oncology
Diagnosis: Genito-urinary - Miscellaneous
Principal Investigator: Lowry MD, Philip
Sub-Investigator(s):
Sponsor: NCI
Details (Identifier #): NCT02502266
Title: NRG-GY005,A Randomized Phase II/III study of the combination of Cediranib and Olaparib compared to Cediranib or Olaparib alone, or Standard of care chemotherapy in women with recurrent platinum-resistant or -refractory ovarian, fallopian tube, or primary peritoneal cancer (COCOS)
Department: Oncology
Diagnosis: Breast
Principal Investigator: Lowry MD, Philip
Sub-Investigator(s):
Sponsor: ALLIANCE
Details (Identifier #): NCT02750826
Title: Alliance A011401, Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Department: Oncology
Diagnosis: Head and Neck
Principal Investigator: Lowry MD, Philip
Sub-Investigator(s):
Sponsor: NRG
Details (Identifier #): NCT03258554
Title: NRG-HN004 Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Stage III-IVB Head and Neck Cancer Who Cannot Take Cisplatin
Department: Oncology
Diagnosis: Breast
Principal Investigator: Lowry MD, Philip
Sub-Investigator(s):
Sponsor: ALLIANCE
Details (Identifier #): NCT02927249
Title: A011502, A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial
Department: Oncology
Diagnosis: Lung- Non-Small Cell
Principal Investigator: Lowry MD, Philip
Sub-Investigator(s):
Sponsor: SWOG
Details (Identifier #): 03373760
Title: S1400F:A Phase II Study of MEDI4736 (Durvalumab) Plus Tremelimumab as Therapy for Patients With Previously Treated Anti-PD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer (Lung-Map Non-Match Sub-Study)
Department: Oncology
Diagnosis: Gastrointestinal - Colon-Rectal
Principal Investigator: Lowry MD, Philip
Sub-Investigator(s):
Sponsor: ALLIANCE
Details (Identifier #): NCT04094688
Title: A021703: Randomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients With Previously Untreated Metastatic Colorectal Cancer (SOLARIS)
Department: Oncology
Diagnosis: Breast- Metastatic
Principal Investigator: Lowry MD, Philip
Sub-Investigator(s):
Sponsor: SWOG
Details (Identifier #): NCT03418961
Title: S1501, Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer
Department: Oncology
Diagnosis: Genito-urinary - Renal
Principal Investigator: Lowry MD, Philip
Sub-Investigator(s):
Sponsor: ALLIANCE
Details (Identifier #): NCT03793166
Title: A031704: PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated Renal Cell Cancer [PDIGREE]
Department: Oncology
Diagnosis: Lung- Non-Small Cell
Principal Investigator: Lowry MD, Philip
Sub-Investigator(s):
Sponsor: SWOG
Details (Identifier #): NCT03971474
Title: S1800A: A Phase II Randomized Study of Ramucirumab Plus MK3475 (Pembrolizumab) Versus Standard of Care for Patients Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)
Department: Oncology
Diagnosis: Lung- Non-Small Cell
Principal Investigator: Lowry MD, Philip
Sub-Investigator(s):
Sponsor: ALLIANCE
Details (Identifier #): NCT02193282
Title: A081105, Randomized Study of Erlotinib or Observation in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)
Department: Oncology
Diagnosis: Lung- Miscellaneous
Principal Investigator: Lowry MD, Philip
Sub-Investigator(s):
Sponsor: ALLIANCE
Details (Identifier #): NCT02194738
Title: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Department: Oncology
Diagnosis: Gastrointestinal - Pancreas
Principal Investigator: Lowry MD, Philip
Sub-Investigator(s):
Sponsor: SynCore
Details (Identifier #): NCT03126435
Title: CT4006: A Randomized Controlled, Open label, Adaptive Phase-3 Trial to Evaluate Safety and Efficacy of EndoTAG-1 Plus Gemcitabine versus Gemcitabine alone in Patients with Measurable Locally Advanced and/or Metastatic Adenocarcinoma of the Pancreas Failed on FOLFIRINOX Treatment
Department: Oncology
Diagnosis: Oncology - General
Principal Investigator: Lowry MD, Philip
Sub-Investigator(s):
Sponsor: ECOG-ACRIN
Details (Identifier #): NCT02201992
Title: E4512, A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Department: Oncology
Diagnosis: Breast
Principal Investigator: Lowry MD, Philip
Sub-Investigator(s):
Sponsor: ECOG-ACRIN
Details (Identifier #): NCT02445391
Title: EA1131, A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy vs. Capecitabine in Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy
Department: Oncology
Diagnosis: Melanoma
Principal Investigator: Lowry MD, Philip
Sub-Investigator(s):
Sponsor: ECOG-ACRIN
Details (Identifier #): NCT02224781
Title: EA6134:DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing); A Phase III Trial
Department: Oncology
Diagnosis: Genito-urinary - Prostate
Principal Investigator: Lowry MD, Philip
Sub-Investigator(s):
Sponsor: ECOG-ACRIN
Details (Identifier #): NCT03419234
Title: EA8153 Cabazitaxel With Abiraterone Versus Abiraterone Alone Randomized Trial for Extensive Disease Following Docetaxel: The CHAARTED2 Trial

Patient Comments

Patient comments are gathered from our Press Ganey Patient Satisfaction Survey and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.

Guthrie Patient: January 2020
*Dr. Lowry is exceptional. I am thankful to have him for my doctor - he listens to every question and concern. He educates me on all that he is doing and why he is following his treatment plan for me. He is not only an exceptional doctor - he is a wonderful coach and mentor to me.
Guthrie Patient: January 2020
I would recommend Guthrie to anyone dealing with cancer
Guthrie Patient: January 2020
Dr. Lowry was very friendly and honest with me. He cared about my issue, but he admitted it wasn't something he could help me with. He made some very helpful suggestions and offered the opportunity to contact him if I have any more issues in the future.
Guthrie Patient: January 2020
Good
Guthrie Patient: January 2020
I do recommend Guthrie/Sayre to all my friends.
Guthrie Patient: November 2019
Dr Lowry is an excellent and knowledgeable doctor. If he would clean up his mouth/speech, it would give him even more credibility. I don't like to hear words like 'shoot', 'dang' coming from a professional. Him using the words does not make me feel like he's relating to me better as a patient. Instead, it puts me on guard, hoping he won't speak more unprofessional slang.
Guthrie Patient: October 2019
Exceptional.
Guthrie Patient: October 2019
Dr . Lowry is a caring and compassionate caregiver.
Guthrie Patient: August 2019
*Dr. Lowry is very personable and knowledgeable. He acted as if he had all the time in the world for me. I left the office feeling reassured and hopeful. Would definitely recommend *Dr. Lowry.
Guthrie Patient: August 2019
I have already recommended the Guthrie Cancer Center, in Corning, to about 5 people. I have also told everyone I know how incredible the staff is. Because I am single, with no kids, I'm on my own. So, I drove myself to chemo and would spend 5 - 6 6 hours there, every other week. Then, I started going weekly for 5 - 6 hours. I also did radiation and I came to the cancer center everyday, for about 25 days. I went to every treatment (over 9 months) alone. But, when I stepped through the doors, I felt like I was there to see my friends.I have gone to Sloan-Kettering and Strong Memorial and, because of the respect, knowledge and compassion I received from Dr. Lowry, I chose to get treated at Guthrie. Having lived in major cities for 30 years, I had access to some pretty amazing doctors. I can honestly say that Dr. Lowry has impressed me more than most other physicians' I've seen over the years.